-
Artelo Q2 Net Loss Declines 33% YoY, Here Is What You Need To Know
Thursday, August 10, 2023 - 11:16am | 565Read More...Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, released its financial results for the three months ended June 30, 2023 and...
-
Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain
Tuesday, June 27, 2023 - 11:06am | 548Read More...Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences, Inc. (NASDAQ: ARTL), presented preclinical data related to ART26.12, Artelo’s novel fatty acid binding protein 5 (FABP5) inhibitor at the 33rd International Cannabinoid Research Society...
-
Artelo Biosciences Presents Groundbreaking Research At Annual CBD Symposium In Canada
Monday, June 26, 2023 - 9:03pm | 424Read More...Artelo Biosciences, Inc. (NASDAQ: ARTL) announced that Professor Saoirse O’Sullivan, vice president of Translational Sciences at Artelo, presented new data at the International Cannabinoid Research Society (ICRS) Symposium in Ontario, CA, highlighting the pharmaceutical properties and...
-
Artelo Biosciences Reveals Positive Pre-Clinical Results Of ART26.12, A Novel FABP5 Inhibitor, In Alleviating Chemotherapy-Induced Pain
Monday, June 27, 2022 - 10:39am | 482Read More...Professor Saoirse O’Sullivan, vice president of translational sciences at Artelo Biosciences Inc., (NASDAQ: ARTL) presented new research results entitled, “Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in chemotherapy-induced pain,” during...
